ELISA Kit to quantify cancer antigen CA125 to diagnose ovarian cancer successfully made

Quantifying CA125 concentrations using ELISA technique is a method that many medical facilities currently use to diagnose early or monitor the treatment progress of ovarian cancer. Diagnosis of ovarian cancer using this technique is about 70-80% accurate compared to the gold standard of clinical and paraclinical tests, X-rays and computed tomography.

Cancer antigen 125 (CA125) is a 220-kDa heavy glycoprotein molecule, encoded by the MUC16 gene located on chromosome 19p13.2. CA 125 has been identified as an important marker in the diagnosis of ovarian cancer, with about 50% of women in the early stages and 80% with late stages having high blood levels of CA125. Quantification of plasma CA125 levels is important for early diagnosis and monitoring of treatment of ovarian cancer. Therefore, the need to use ELISA kits at medical facilities is huge.

In recent years, the production of ELISA kits to diagnose ovarian cancer has attracted attention in many parts of the world. Although there are many commercial kits circulating on the market, no research on making ELISA kits to quantify CA125 antigen has been published to date. Utility solution patent 0003052 was granted by the National Office of Intellectual Property to Assc. Prof. Dr. Nguyen Thi Xuan and scientists from the Institute of Genome Research mentioned the method of producing ELISA kits used to quantify cancer antigen CA125 to diagnose ovarian cancer.


The ELISA kit is made according to a new useful solution that is unique and different from other kits in the world in that the capture antibody of the kit is manufactured and purified by the research team from the polyclonal antibody obtained from serum of mice immunized with CA125 antigen. The self-produced polyclonal anti-CA125 antibody binds specifically to the CA125 antigen and the commercial HRP-binding monoclonal anti-CA125 antibody in an ELISA reaction. Polyclonal antibody CA125 can be produced in large quantities of high quality and without shipping or import fees.

The ELISA kit uses a new patented process and is a useful solution with the same quality as commercial kits currently on the market but is much cheaper (3-5 times), contributing to lowering costs of testing, ensuring that most middle-aged women are screened for the disease.

This useful solution belongs to the pilot production project "Completing the technological process of producing CA 15-3, CA 125 and HCG-β antigen quantification kits to serve the diagnosis of breast, ovarian and testicular cancer”, code number KC.10.DA06/16-20, funded by the Ministry of Science and Technology.


Translated by Phuong Huyen
Link to Vietnamese version


Related news